Metformin Actavis (Metformin Hydrochloride)

Metformin acts primarily by activating AMP‑activated protein kinase (AMPK) in the liver, which suppresses gluconeogenesis. It also increases insulin‑mediated glucose uptake in muscle and fat tissue and modestly reduces intestinal glucose absorption, collectively lowering blood glucose without stimulating insulin secretion.

The dose of Metformin Actavis is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Typical adult regimens start with a low dose and are titrated upward, but the exact strength and schedule are determined by the prescriber.

Safety of Metformin during pregnancy or lactation should be evaluated by a qualified clinician. While some guidelines allow its use when benefits outweigh risks, the drug crosses the placenta and is excreted in breast milk, so a healthcare provider must assess each case before continuation.

To order Metformin Actavis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, Metformin does not stimulate insulin release, so it carries a lower risk of hypoglycaemia when used alone. Unlike newer agents such as GLP‑1 receptor agonists, Metformin is inexpensive and has a long safety record, though it may cause gastrointestinal upset more frequently.

Metformin Actavis should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency throughout its shelf life.

Metformin Actavis is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not crush or chew the tablets unless directed.

The most serious risk of Metformin is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, liver disease, or excessive alcohol intake. Other serious concerns include severe skin reactions such as Stevens‑Johnson syndrome and significant hepatic dysfunction.

Metformin is contraindicated in patients with known hypersensitivity to metformin or other biguanides, severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and those receiving radiographic contrast studies that may affect renal function. Clinicians should evaluate each individual’s medical history before prescribing.